We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PER market cap is 8.11M. The company's latest EPS is AUD -0.0132 and P/E is -0.76.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 741k | 633k | 1.78M | 1.58M | 2.35M |
| Operating Income | -5.93M | -8.05M | -5.83M | -11.77M | -12.53M |
| Net Income | -5.91M | -8.06M | -5.81M | -11.38M | -11.92M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 5.35M | 7M | 22.44M | 12.84M | 14.53M |
| Total Liabilities | 821k | 1.27M | 1.3M | 2.87M | 5.17M |
| Total Equity | 4.53M | 5.73M | 21.14M | 9.98M | 9.36M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -3.95M | -5.83M | -7.81M | -8.15M | -10.12M |
| Investing | -10k | -8k | -4k | -29k | -4k |
| Financing | 5.11M | 7.8M | 21.02M | -86k | 11.02M |
| Market Cap | 8.11M |
| Price to Earnings Ratio | -0.76 |
| Price to Sales Ratio | 3.85 |
| Price to Cash Ratio | 0.76 |
| Price to Book Ratio | 0.96 |
| Dividend Yield | - |
| Shares Outstanding | 901.54M |
| Average Volume (1 week) | 12.15M |
| Average Volume (1 Month) | 38.01M |
| 52 Week Change | -84.48% |
| 52 Week High | 0.14 |
| 52 Week Low | 0.005 |
| Spread (Intraday) | 0 (10%) |
| Company Name | Percheron Therapeutics Ltd |
| Address |
14 wallace avenue melbourne, victoria 3142 |
| Website | https://www.antisense.com.au |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
